The minimal invasive surfactant therapy: experience from a low resource setting.

OBJECTIVE: To evaluate all cases managed with the Minimal Invasive Surfactant Therapy (MIST) and its effect on outcome.

BACKGROUND: Respiratory distress syndrome (RDS), a major cause of morbidity and mortality in preterm new-borns is common in sub-Saharan Africa. Surfactant replacement therapy (SRT) is less practiced and the new MIST is just introduced in Asaba, Nigeria.

METHODS: This descriptive survey recruited new-borns of consenting parents who provided for the surfactant and other commodities. Demographic characteristics were obtained. Intervention included MIST Surfactant, nasal bubble Continuous Positive Airway Pressure (n b-CPAP). Aminophylline or Caffeine, early breast milk feeding and Kangaroo mother care (KMC). Data were collected over a 1-year period and Standard statistical methods were used for data analysis.

RESULTS: From 1 May 2019 to 30 April 2020, there were 1801 live births, preterm birth rate of 10.72% (193/1801) at the FMC, Asaba. Admissions to the Neonatal Unit (NNU) comprised a total of 731 newborn: 270 preterms. Of these preterm; 52(19.26%) were extreme preterms; 122 (16.15%) very preterm. Of these 731 total admissions there were 104 (14.23%). Their gestational ages (GA) ranged from 24 to 38 weeks and birthweights from 600 to 3400 g. A total of 51 Newborns received surfactant. Their GA ranged from 24 to 38 Weeks; birth weights 600 to 3400 g. These comprised 48 preterm and 3 terms. All 51 infants with RDS who received MIST surfactant included 48 preterms and 3 terms with perinatal Asphyxia and Meconium Aspiration Syndrome. The obstetric management of five mothers of early preterm included two doses of antenatal cortico-steroids prior to delivery. MIST was successful in 47 of 51 (92.2%) cases. Age range at administration was one to 48 h. Duration of n-bCPAP post surfactant: ranged 6 h to 96 h: 4 babies were weaned off CPAP within 24 h; 12 babies at <48 h, another 9 at <72 h; and 20 beyond 96 h. Five babies received a second dose of MIST after 48 h of the first dose. Twelve of 51 (23.5%) babies died; 4 at 48 h, 2 at 72 h, 3at 96 h and 3 beyond 7 days. Prior to the MIST, respiratory distress (RD) and severity rating as indicated by the Silverman Anderson Score (SA) scores in the survivors ranged from 6/10 to 8/10.

CONCLUSIONS: The MIST, at FMC Asaba, improves outcome of the extreme preterm. Financial barriers remain a major constraint to its use.